Kare Schultz Becomes Lundbeck’s CEO As New Launches Gather Pace
This article was originally published in The Pink Sheet Daily
One of the first priorities for Lundbeck’s new chief executive will be supporting new product launches worldwide to boost the Danish company’s geographic and product diversification.
You may also be interested in...
Candidates for the post in the Danish biotech are likely to have a commercial background, as Wiinberg-inspired strategy of geographic expansion and a growing a pipeline of CNS products continues to bear fruit.
Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.